TABLE 1 | Recent patent applications related to motilin agonists, ghrelin agonists and cholecystokinin antagonists
From the following article:
Nature Reviews Drug Discovery 7, 194-195 (March 2008)
doi:10.1038/nrd2548
| Patent number(s) | Assignee(s) | Subject |
|---|---|---|
| WO 2007014258 | Société de Conseils de Recherches et d'Applications Scientifiques | Describes new peptide or peptidomimetic compounds — including ghrelin agonists — that are useful for treating conditions such as inflammatory bowel disease and ulcerative colitis. |
| EP 1781311 | Elixir Pharmaceuticals | Claims a method of treating disorders of the stomach, intestine or duodenum via administering a ghrelin receptor agonist that induces the secretion of growth hormone, modulation of mesenteric nerve activity or both. |
| EP1773869 | Tranzyme Pharma | Describes novel conformationally defined macrocyclic compounds that are selective ghrelin receptor agonists; useful for treating metabolic and/or endocrine disorders and gastrointestinal disorders. |
| EP 1789067
US 20070191283 | Sapphire Therapeutics | Claims a method of stimulating the motility of the gastrointestinal system using ghrelin agonists; useful for treating or preventing opioid-induced constipation or diabetes-related gastroparesis. |
| EP 1742655
JP 2007532495 | Gastrotech Pharma | Describes the use of a ghrelin agonist for treating weight loss, cachexia, disrupted sleep pattern and pathological conditions associated with insulin resistance. Use of this compound increases hypothalamic receptor expression levels and prevents the compensatory increase in food intake. |
| WO2007108990
WO2007126792 US2007238662 | M. Liat | A series of patents describing the use of ghrelin splice variants for treating high-cholesterol complications, diabetes, anorexia/cachexia and/or malnutrition, and appetite stimulation. |
| JP 2007521320 | Kosan Biosciences et al. | Describes new N-desmethyl-N-substituted-11-deoxyerythromycin compounds that act as motilin receptor agonists with enhanced prokinetic activity; useful for treating gastroparesis, gastroesophageal reflux diseases, gall-bladder stasis, irritable bowel syndrome and gastritis. |
| EP 1835920 | Chugai Pharmaceutical | Describes the use of a motilin agonist comprising an erythromycin derivative for treating gastroparesis symptoms in individuals with functional gastritis or diabetes. The compound is safe and suitable for continuous medication over an extended period. |
| US 20070249698 | Janssen Cilag | Describes new substituted imidazole compounds that are selective cholecystokinin 1 receptor agonists or antagonists; useful for treating gastrointestinal motility disorders, functional bowel disease, biliary colic and anorexia. |
| JP 2007501841
JP 2007501842 | Janssen Cilag | Describes new amidophenyl-sulphonylamino-quinoxaline compounds that are potent cholecystokinin 2 antagonists; useful for treating gastroduodenal ulcer, anxiety and colon cancer. |
| US 20070123718 | University of Aston | Describes new 4-amino-2(5H)-furanone derivatives that are selective cholecystokinin 1 and 2 ligands; useful for treating gastroesophageal reflux disease, ulcer, excess pancreatic or gastric secretion, acute pancreatitis and gastric motility disorders. |
| US 20070082892 | James Black Foundation | Describes new benzotriazepine derivatives that are cholecystokinin 2 antagonists that show synergistic effects on the reduction of acid secretion in combination with a proton-pump inhibitor; useful for treating gastrointestinal disorders. |
Download file
If the slide opens in your browser, select "File > Save As" to save it.
